Meta-analytic evidence examining associations of circulating leptin and adiponectin with prostate cancer risk reveals modest associations, with adiponectin showing a weak inverse association with overall prostate cancer (odds ratio: 0.96 per 2.5 μg/mL increase, 95% CI: 0.93-0.99) and leptin showing no consistent association overall, though weak evidence supports association with aggressive disease [47]. The gene discussed is ADIPOQ; the disease is prostate cancer.